Health · 1 sources covering this

STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial

Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
Pfizer said an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/3af32ae5871d96d56b5220959efff44020f1e511"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial"></iframe>

STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial

How 1 sources are covering this

STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial

More from Health

Trump administration targets disability integration mandate in DOJ memo

A look at the science that's been lost on long COVID

Trouble getting weight loss drugs covered by insurance? Here's what to know

How to prepare for the rise of solo agers

Reader

Trust & legal

Across the network